Compare IXHL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IXHL | RFL |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 54.4M |
| IPO Year | N/A | N/A |
| Metric | IXHL | RFL |
|---|---|---|
| Price | $0.46 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.6M | 92.7K |
| Earning Date | 11-14-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $12,000.00 | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.08 | $1.17 |
| 52 Week High | $2.25 | $3.19 |
| Indicator | IXHL | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 43.20 |
| Support Level | $0.35 | $1.20 |
| Resistance Level | $0.50 | $1.29 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 80.58 | 50.00 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.